Searched for
DRUG PRICING INTERVENTION
Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are backThe government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicine...- NPPA list brings little relief: No price cut for 25% cancer drugsNearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across ...
- India’s drug pricing policy must balance affordability, medicine availability and pharma industry growthThe Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...
- Cancer care can be cheaper: 6 steps to cut drug costsIndia has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...
- Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...
- Hospitals overcharge patients upto 700% on medicines while India makes some of the world’s lowest priced drugs: Centre admits to SCGovt has told Supreme Court that hospitals overcharging patients for medicines and medical consumables is a malpractice. Its affidavit cite...
- Sahajanand Medical Technologies shares list at 8% premium over IPO price on NSEThe Rs 475.48 crore IPO comprised an offer for sale (OFS) of 1.38 crore shares. Since the issue was entirely an OFS, the company will not r...
- Sahajanand Medical Technologies IPO Day 3: GMP at 7%; check subscription status and key detailsSahajanand Medical Technologies’ IPO enters its final bidding day with 82% subscription on Day 2 and a 7% grey market premium. The Rs 475.4...
- The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
- Sahajanand Medical Technologies IPO Day 2: Check GMP, subscription status and key detailsSahajanand Medical Technologies IPO entered Day 2 on October 16, 2026, with a 12% GMP and 34% subscription on Day 1. The Rs 475.48-crore of...
- Sahajanand Medical Technologies IPO opens for subscription. Check GMP, price band and key detailsSahajanand Medical Technologies IPO opened for subscription on October 15, 2026, aiming to raise Rs 475.48 crore through an entirely offer-...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
- Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicinesThe Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning wh...
- IPO calendar: After a week of lull, 5 companies to raise nearly Rs 1,600 crore this weekFive IPOs are scheduled to open for subscription next week, including mainboard issues from HD Fire Protect, Fusion CX and Sahajanand Medic...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- Karnataka flags 52x mark-up on cancer drugs, seeks Centre's interventionKarnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs a...
- H1N1 dominates India's flu cases, accounts for 75 pc of positive samples: WHO reportRecent WHO surveillance data reveals that H1N1 accounts for a significant percentage of influenza cases in India. The data indicates that H...
- Kerala HC says exorbitant drug prices can trigger government intervention in patented medicinesThe Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the...
Load More
